Literature DB >> 21564077

Preservation of fertility in females with haematological malignancy.

Jacques Donnez1, Marie-Madeleine Dolmans.   

Abstract

Several options are currently available for the preservation of fertility in cancer patients: embryo cryopreservation, oocyte cryopreservation or ovarian tissue cryopreservation. The choice of the most suitable strategy for preserving fertility depends on different parameters: the type and timing of chemotherapy, the type of cancer, the patient's age and the partner status. Cryopreservation of ovarian tissue is the only option available for prepubertal girls and woman who cannot delay the start of chemotherapy. So far, 15 live births have been obtained after orthotopic transplantation of cryopreserved ovarian tissue.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21564077     DOI: 10.1111/j.1365-2141.2011.08723.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

1.  Retransplantation of cryopreserved ovarian tissue: the first live birth in Germany.

Authors:  Andreas Müller; Katja Keller; Jennifer Wacker; Ralf Dittrich; Gudrun Keck; Markus Montag; Hans Van der Ven; David Wachter; Matthias W Beckmann; Wolfgang Distler
Journal:  Dtsch Arztebl Int       Date:  2012-01-09       Impact factor: 5.594

2.  Effect of Imatinib Coadministration on in Vitro Oocyte Acquisition and Subsequent Embryo Development in Cyclophosphamide-Treated Mice.

Authors:  Eun Kyung Chun; Byung Chul Jee; Ju Yeong Kim; Seok Hyun Kim; Shin Yong Moon
Journal:  Reprod Sci       Date:  2014-01-08       Impact factor: 3.060

3.  Combined strategy for fertility preservation in an oncologic patient: vitrification of in vitro matured oocytes and ovarian tissue freezing.

Authors:  Clara González; Marta Devesa; Montserrat Boada; Buenaventura Coroleu; Anna Veiga; Pere N Barri
Journal:  J Assist Reprod Genet       Date:  2011-09-02       Impact factor: 3.412

4.  Detection of non-Hodgkin's lymphoma in ovarian cortex pieces during the process of cryopreservation.

Authors:  Héloïse Gronier; Louis Terriou; Geoffroy Robin; Agnès Wacrenier; Brigitte Leroy-Martin; Catherine Lefebvre; Denis Vinatier; Franck Morschhauser; Christine Decanter
Journal:  J Assist Reprod Genet       Date:  2014-07-15       Impact factor: 3.412

5.  Viability assessment of fresh and frozen/thawed isolated human follicles: reliability of two methods (Trypan blue and Calcein AM/ethidium homodimer-1).

Authors:  Sandra Sanfilippo; Michel Canis; Lemlih Ouchchane; Revaz Botchorishvili; Christine Artonne; Laurent Janny; Florence Brugnon
Journal:  J Assist Reprod Genet       Date:  2011-10-27       Impact factor: 3.412

Review 6.  Fertility preservation through gonadal cryopreservation.

Authors:  Lalitha Devi; Sandeep Goel
Journal:  Reprod Med Biol       Date:  2016-03-11

7.  The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Authors:  Jiangxue Qu; Yuehan Li; Shujie Liao; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice.

Authors:  Bei-Jia Kang; Yan Wang; Long Zhang; Zhun Xiao; Shang-Wei Li
Journal:  J Assist Reprod Genet       Date:  2015-12-28       Impact factor: 3.412

9.  Preserving fertility in female patients with hematological malignancies: the key points.

Authors:  Mahmoud Salama; Antoinette Anazodo; Teresa K Woodruff
Journal:  Expert Rev Hematol       Date:  2019-05-06       Impact factor: 2.929

10.  Future Directions in Oncofertility and Fertility Preservation: A Report from the 2011 Oncofertility Consortium Conference.

Authors:  Kate E Waimey; Francesca E Duncan; H Irene Su; Kristin Smith; Harlan Wallach; Kemi Jona; Christos Coutifaris; Clarisa R Gracia; Lonnie D Shea; Robert E Brannigan; R Jeffrey Chang; Mary B Zelinski; Richard L Stouffer; Robert L Taylor; Teresa K Woodruff
Journal:  J Adolesc Young Adult Oncol       Date:  2013-03       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.